|
Session 3
09.00 - 11.00
Genetics, Aetiology, Epidemiology, Neuroimaging & Underlying Neuronal Mechanisms
Chair: M. Casas (ES) |
09.00 |
Keynote address: Genetics approaches to alcoholism can lead to new prevention and treatment strategies |
H. Gurling (UK) |
| |
09.45 |
Biological Indicators of Substance Misuse |
|
| |
10.05 |
Imaging Usual Addictions: Alcohol and Tobacco |
J.L. Martinot (FR) |
| |
10.25 |
Gene Variants and Substance Use Disorders: Neuroendocrine and Clinical Correlates |
G. Gerra (IT) |
| |
10.45 |
Discussion |
All |
Session 4
11.30 - 13.30
Dual Diagnosis
Chair: A. Uchtenhagen (CH) |
11.30 |
Keynote address: Dual diagnosis: clinical implications of psychiatric comorbidity in substance abusers |
M. Torrens (ES) |
| |
12.20 |
Methamphetamine (TBC) |
J. Marsden (UK) |
| |
12.40 |
Cost-effectiveness of treatment |
C. Godfrey (UK) |
| |
13.00 |
Dual diagnosis patients in substance use disorder treatment programs in Switzerland and the USA: A cross- national comparison of outcomes |
F. Moggi (CH) |
| |
13.20 |
Open Forum |
ALL |
13.30 |
Lunch break and free time |
15.00 - 16.15
POSTER SESSION |
15.30 |
Oral Poster Presentations |
16.00 |
Poster Awards |
16.30 - 17.50
Smoking Cessation I
Issues Mechanisms & Current Treatments |
16.30 |
Keynote address: Implementing Non-Smoking initiatives for patients and their impact on the individual |
H. Tønnesen (DK) |
| |
17.00 |
Smoking and Psychiatric Disorders |
M. Farrell (UK) |
| |
17.20 |
New Ways of Using Nicotine Replacement Therapies |
P. Aveyard (UK) |
| |
17.40 |
The role of exercise in managing cigarette cravings, withdrawal symptoms and smoking behaviour |
A. Taylor (UK) |
18.10 - 19.40
Smoking Cessation II
New Agents on Smoking Cessation |
18.10 |
Overview of current picture and trends in smoking cessation |
K. Fagerstrom (SE) |
18.50 |
Varenicline for smoking cessation |
H. McRobbie (NZ) |
19.30 |
Discussion |
ALL |
|
|
